aggrecan Antibody (5J14): sc-70334
- aggrecan Antibody (5J14) is a mouse monoclonal IgG1 κ, cited in 3 publications, provided at 200 µg/ml
- raised against human articular cartilage aggrecan
- recommended for detection of aggrecan of human origin by WB, IP, IF and IHC(P)
- See aggrecan (4F4): sc-33695 for aggrecan antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for aggrecan Antibody (5J14) for WB and IHC(P) applications. These reagents are now offered in bundles with aggrecan Antibody (5J14) (see ordering information below).
QUICK LINKS
SEE ALSO...
Aggrecan Antibody (5J14) is a mouse monoclonal IgG1 antibody that detects aggrecan in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Aggrecan is a large chondroitin sulfate proteoglycan that plays a crucial role in maintaining the structural integrity and function of cartilage. Anti-aggrecan antibody (5J14) targets proteins primarily located in the extracellular matrix of cartilage, where aggrecan forms aggregates with hyaluronan and link proteins, creating a resilient and compressive network essential for the mechanical properties of hyaline cartilage. This structural arrangement allows aggrecan to withstand compressive forces, making aggrecan vital for joint function and mobility. Notably, aggrecan degradation is often associated with various forms of inflammatory arthritis, leading to cartilage loss and joint dysfunction. Aggrecan monoclonal antibody (5J14) serves as an invaluable tool for researchers studying cartilage biology, disease mechanisms, and potential therapeutic targets in conditions characterized by cartilage degradation.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
aggrecan Antibody (5J14) References:
- Chondrodysplasia of gene knockout mice for aggrecan and link protein. | Watanabe, H. and Yamada, Y. 2002. Glycoconj J. 19: 269-73. PMID: 12975605
- Aggrecan modulation of growth plate morphogenesis. | Domowicz, MS., et al. 2009. Dev Biol. 329: 242-57. PMID: 19268444
- Glucose enhances aggrecan expression in chondrocytes via the PKCα/p38-miR141-3p signaling pathway. | Wu, TJ., et al. 2018. J Cell Physiol. 233: 6878-6887. PMID: 29319178
- Aggrecan Turnover in Women with Rheumatoid Arthritis Treated with TNF-α Inhibitors. | Szeremeta, A., et al. 2020. J Clin Med. 9: PMID: 32392807
- Aggrecan and COMP Improve Periosteal Chondrogenesis by Delaying Chondrocyte Hypertrophic Maturation. | Caron, MMJ., et al. 2020. Front Bioeng Biotechnol. 8: 1036. PMID: 32984292
- Clinical phenotype and musculoskeletal characteristics of patients with aggrecan deficiency. | Alexandrou, E., et al. 2022. Am J Med Genet A. 188: 1193-1203. PMID: 35001504
- Deletion of Axin1 in aggrecan-expressing cells leads to growth plate cartilage defects in adult mice. | Yi, D., et al. 2024. Genes Dis. 11: 101147. PMID: 38515941
- Serum ARGS-aggrecan in a phase 2 clinical trial targeting osteoarthritis. | Larsson, S., et al. 2024. Osteoarthritis Cartilage. 32: 1463-1470. PMID: 38862084
- Deletion of Bmal1 in aggrecan-expressing cells leads to mouse temporomandibular joint osteoarthritis. | Liao, L., et al. 2024. J Bone Miner Metab. 42: 529-537. PMID: 38981876
- Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. | Watanabe, H., et al. 1998. J Biochem. 124: 687-93. PMID: 9756610
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
aggrecan Antibody (5J14) | sc-70334 | 200 µg/ml | $316.00 | |||
aggrecan Antibody (5J14): m-IgG Fc BP-HRP Bundle | sc-539266 | 200 µg Ab; 10 µg BP | $354.00 | |||
aggrecan Antibody (5J14): m-IgG1 BP-HRP Bundle | sc-541365 | 200 µg Ab; 20 µg BP | $354.00 |